Search

Displaying results 3691 - 3700 of 8698 in total
  1. Drug

    Ebvaciclib

    go.drugbank.com/drugs/DB18967
    Investigational

    Ebvaciclib is under investigation in clinical trial NCT03519178 (A Study of PF-06873600 in People With Cancer).

  2. Drug

    Mosliciguat

    go.drugbank.com/drugs/DB19425
    Investigational

    Mosliciguat is under investigation in clinical trial NCT06635850 (A Phase 2 Study of Mosliciguat in PH-ILD).

  3. Drug

    ING-1

    go.drugbank.com/drugs/DB05831
    Investigational

    It is an attractive target for immunotherapy.

  4. Drug

    Raltegravir

    go.drugbank.com/drugs/DB06817
    ApprovedInvestigational

    Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Saruparib

    go.drugbank.com/drugs/DB18982
    Investigational

    Saruparib is under investigation in clinical trial NCT06380751 (Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative

  6. Drug

    Parathyroid hormone

    go.drugbank.com/drugs/DB05829
    ApprovedInvestigational

    Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence

  7. Drug

    Veglin

    go.drugbank.com/drugs/DB05890
    Experimental

    VEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma … Veglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in the ongoing struggle to combat malignant mesothelioma.

  8. Drug

    Acitretin

    go.drugbank.com/drugs/DB00459
    ApprovedInvestigational

    An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.

    Categories: Antipsoriatics for Systemic Use, Retinoids for Treatment of Psoriasis
  9. Drug

    Treprostinil

    go.drugbank.com/drugs/DB00374
    ApprovedInvestigational

    However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature. … Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  10. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical … In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity.